Corbet Cyril
Pole of Pharmacology and Therapeutics, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium.
Front Pharmacol. 2018 Jan 4;8:958. doi: 10.3389/fphar.2017.00958. eCollection 2017.
Normal and cancer stem cells (CSCs) share the remarkable potential to self-renew and differentiate into many distinct cell types. Although most of the stem cells remain under quiescence to maintain their undifferentiated state, they can also undergo cell divisions as required to regulate tissue homeostasis. There is now a growing evidence that cell fate determination from stem cells implies a fine-tuned regulation of their energy balance and metabolic status. Stem cells can shift their metabolic substrate utilization, between glycolysis and mitochondrial oxidative metabolism, during specification and/or differentiation, as well as in order to adapt their microenvironmental niche. Pyruvate appears as a key metabolite since it is at the crossroads of cytoplasmic glycolysis and mitochondrial oxidative phosphorylation. This Review describes how metabolic reprogramming, focusing on pyruvate utilization, drives the fate of normal and CSCs by modulating their capacity for self-renewal, clonal expansion/differentiation, as well as metastatic potential and treatment resistance in cancer. This Review also explores potential therapeutic strategies to restore or manipulate stem cell function through the use of small molecules targeting the pyruvate metabolism.
正常干细胞和癌症干细胞(CSCs)都具有自我更新和分化为多种不同细胞类型的显著潜能。尽管大多数干细胞处于静止状态以维持其未分化状态,但它们也可根据需要进行细胞分裂以调节组织稳态。现在越来越多的证据表明,干细胞的细胞命运决定意味着对其能量平衡和代谢状态的精确调节。在分化过程中和/或分化后,以及为了适应其微环境,干细胞可以在糖酵解和线粒体氧化代谢之间切换其代谢底物利用方式。丙酮酸似乎是一种关键代谢物,因为它处于细胞质糖酵解和线粒体氧化磷酸化的交叉点。本综述描述了以丙酮酸利用为重点的代谢重编程如何通过调节正常干细胞和癌症干细胞的自我更新、克隆扩增/分化能力,以及癌症中的转移潜能和治疗抗性来驱动其命运。本综述还探讨了通过使用靶向丙酮酸代谢的小分子来恢复或操纵干细胞功能的潜在治疗策略。